Latest News and Press Releases

TORONTO, April 02, 2025 (GLOBE NEWSWIRE) -- Testicular Cancer Awareness Month is here, and Movember – the world’s leading men’s health charity – is asking men to get hands-on with their health...

BALTIMORE, April 01, 2025 (GLOBE NEWSWIRE) -- Two’s company, but a lump is a crowd! April is Testicular Cancer Awareness Month, and the Urology Care Foundation (UCF), the official foundation of the...

TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- It’s Movember 1 and Canada’s hairiest campaign is back to raise awareness, education and important funds for men’s health. This year, Olympian and...

TORONTO, 01 oct. 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) sont de retour à l'occasion de la campagne la plus poilue du Canada, le 1er Novembre! Cette année, Movember est fier de s'associer à...

TORONTO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) are back as Canada’s hairiest campaign returns on Movember 1! This year, Movember is proud to be partnering with Olympian and...

Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...

Follow-up-Daten zeigen ermutigende Anzeichen für eine klinische Anti-Tumor-Aktivität sowie ein kontrollierbares Sicherheits- und Verträglichkeitsprofil; Daten bauen auf den positiven...

Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in...

Erster BioNTech-Produktkandidat, der von der Europäischen Arzneimittelagentur den Priority-Medicines (PRIME)-Status erhält; dies ermöglicht eine verstärkte regulatorische Unterstützung bei der...

First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the...